Literature DB >> 26887826

Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when?

Focke Ziemssen1, Karl Ulrich Bartz-Schmidt2, Spyros Dimopoulos2.   

Abstract

Keywords:  Natural history; Ocriplasmin; SD-OCT; Vitrectomy; Vitreomacular adhesion

Mesh：

Substances：

Year:  2016        PMID： 26887826     DOI： 10.1007/s00417-016-3301-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  8 in total

1.  Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern(®) Guidelines.

Authors:  James C Folk; Ron A Adelman; Christina J Flaxel; Leslie Hyman; Jose S Pulido; Timothy W Olsen
Journal:  Ophthalmology       Date:  2015-11-12       Impact factor: 12.079

2.  Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.

Authors:  Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller
Journal:  N Engl J Med       Date:  2012-08-16       Impact factor: 91.245

3.  Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy?

Authors:  Spyridon Dimopoulos; Karl-Ulrich Bartz-Schmidt; Faik Gelisken; Kai Januschowski; Focke Ziemssen
Journal:  Br J Ophthalmol       Date:  2014-10-23       Impact factor: 4.638

4.  The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole.

Authors:  Jay S Duker; Peter K Kaiser; Susanne Binder; Marc D de Smet; Alain Gaudric; Elias Reichel; SriniVas R Sadda; Jerry Sebag; Richard F Spaide; Peter Stalmans
Journal:  Ophthalmology       Date:  2013-09-17       Impact factor: 12.079

5.  Post-Market Experience With Ocriplasmin Including Chronic Electrophysiologic Changes.

Authors:  Kent W Small; Fadi S Shaya; Maribel La Fontaine
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-10       Impact factor: 1.300

6.  Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.

Authors:  Irini Chatziralli; George Theodossiadis; Efstratios Parikakis; Ioannis Datseris; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-05       Impact factor: 3.117

7.  Cost evaluation of surgical and pharmaceutical options in treatment for vitreomacular adhesions and macular holes.

Authors:  Jonathan S Chang; William E Smiddy
Journal:  Ophthalmology       Date:  2014-05-15       Impact factor: 12.079

8.  A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit).

Authors:  Peter Stalmans
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-22       Impact factor: 3.117
  8 in total
  1 in total

Review 1.  Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Authors:  Irini Chatziralli; George Theodossiadis; Paraskevi Xanthopoulou; Michael Miligkos; Sobha Sivaprasad; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-30       Impact factor: 3.117
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.